<DOC>
	<DOCNO>NCT02161224</DOCNO>
	<brief_summary>The effect moderately diminish liver function exposure , safety tolerability single dose FG-4592 study male female subject . The result compare data gain subject normal liver function .</brief_summary>
	<brief_title>A Study Investigate Exposure Safety Tolerability Single Dose FG-4592 Subjects With Moderately Diminished Liver Function Compared Those With Normal Liver Function</brief_title>
	<detailed_description>The effect moderate hepatic impairment pharmacokinetics ( PK ) , safety tolerability single dose FG-4592 male female subject investigate . Data obtain subject compare data BMI- , age- sex-matched subject normal hepatic function . Both group consist 8 subject . Screening take place Days -22 -2 admission clinical unit Day -1 . Administration trial medication take place Day 1 fast condition . Healthy subject discharge Day 5 subject moderate hepatic impairment Day 7 , reason extend stay . An end-of-study visit ( ESV ) take place 5 9 day ( early ) discharge . Safety assessment perform throughout study .</detailed_description>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Both healthy subject subject moderate hepatic impairment : Independent Ethics Committee ( IEC ) approve write Informed Consent privacy language per national regulation must obtain subject prior studyrelated procedure ( include withdrawal prohibit medication , applicable ) . Male subject female spouse/partners childbearing potential must use highly effective contraception consist 2 form birth control ( 1 must barrier method ) start screen continue throughout study period 90 day study drug administration . In addition , subject moderate hepatic impairment must also meet follow inclusion criterion : Subject ChildPugh classification Class B ( moderate , 7 9 point ) liver function impairment [ screening ] . Both healthy subject subject moderate hepatic impairment : Female subject pregnant within 6 month prior screen breastfeed within 3 month screen . Subject know suspected hypersensitivity FG4592 , component formulation use . In addition , healthy subject must also NOT meet follow exclusion criterion : Subject liver function test ( LFT ) ( Aspartate Aminotransferase [ AST ] , Alanine Aminotransferase [ ALT ] , Alkaline Phosphatase [ ALP ] , Gamma Glutamyl Transferase [ GGT ] , Total Bilirubin [ TBL ] upper limit normal ( ULN ) . In case assessment may repeat [ Day1 ] . In addition , subject moderate hepatic impairment must also NOT meet follow exclusion criterion : Subject previous liver transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>FG-4592</keyword>
	<keyword>Single dose</keyword>
	<keyword>Moderate hepatic impairment</keyword>
</DOC>